Omkar Spl.Chem.

- The company is exploring a rights issue for equity fundraising but no final decision has been taken yet. Once finalized, the company will notify investors about the size, pricing, and utilization of funds (page 4, 8, 16). - They are currently identifying opportunities and considering debt as an alternative option for funding acquisitions, but no concrete announcement has been made so far (page 12). - The company is gradually repaying existing debt at about ₹5-15 crores every quarter, which is reducing the debt level and finance cost (pages 15-16, 10, 11). - No major CAPEX is planned currently; only maintenance CAPEX of ₹4-5 crores (page 7). - Promoter loans of ₹60 crores form part of total debt ₹204 crores (page 10).

- The company has completed major CAPEX in previous years, including capacity expansion by about 800 metric tonnes per annum. - Going forward, only maintenance CAPEX of around INR 4-5 crores is planned, with no major new CAPEX anticipated. - The company is working on a rights issue for capital raising; the board has given in-principle approval but exact details (size, pricing) are under consideration. - The rights issue proceeds are likely aimed at funding acquisitions and business expansion, although no concrete announcements have been made yet. - They are exploring acquisitions and are in the identification process but will announce once finalized. - Strategic focus includes scaling new products in sectors like fragrances, ceramics, flavors with international tie-ups. - No major fresh CAPEX except for growth via product scale-up and acquisitions planned in the near term.

- The company expects a conservative growth rate of about 15% year-on-year in sales/revenue (Page 15, 7). - New product segments like fragrances, flavors, and nutraceuticals are being scaled up, contributing to revenue diversification (Page 3, 4, 13). - Export revenues, currently around 20%, are expected to increase going forward (Page 8). - New products in fragrances and food sectors may grow from 1-2% contribution to about 10% in coming quarters (Page 5). - The company targets over 30% of sales coming from patented products in the future (Page 10). - Product mix optimization and diversification into high-margin segments (30-35% gross margins) will support revenue growth (Page 11, 15). - The global market opportunity for new products is estimated around INR 500-600 crores (Page 11, 4). - Despite pharma sector slowdown, company expects demand to normalize and growth to continue steadily (Page 7).

- The company expects a conservative revenue growth of about 15% year-on-year (Pravin Herlekar, Page 7 & 15). - Margins, especially EBITDA margins, are expected to be maintained around 17%-18%, with a possible variation of ±1% depending on product mix (Page 12). - New product segments like fragrances, food, and nutraceuticals, having higher gross margins (around 30%-35%), are expected to support and potentially improve overall EBITDA margins (Pages 11, 15). - Expansion in exports from the current ~20% of revenue is anticipated, which may further boost top-line growth (Page 8). - The diversified product portfolio and ability to switch product mix quickly helps mitigate risks from sector-specific downturns, supporting steady earnings growth (Page 7). - Overall, operating profits and net profits have shown improvements recently, with a 22% EBITDA growth and 38% net profit growth year-on-year in Q1 FY18 (Page 3).

The transcript from the provided pages does not specifically mention the current or expected order book or pending orders for Omkar Speciality Chemicals Limited. There are no direct references or data related to order book status or pending orders discussed during the Q&A or presentations on these pages. If you need detailed information about order book or pending orders, it might be available in other sections of the full report or company filings.